共 221 条
[1]
Attal M(2017)Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma N Engl J Med 376 1311-1320
[2]
Lauwers-Cances V(2022)Triplet therapy, transplantation, and maintenance until progression in myeloma N Engl J Med 387 132-147
[3]
Hulin C(2003)High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Engl J Med 348 1875-1883
[4]
Leleu X(2014)Survival of multiple myeloma patients aged 65–70 years in the era of novel agents and autologous stem cell transplantation A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network Acta Haematol 132 211-219
[5]
Caillot D(2012)Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma Leuk Lymphoma 53 118-122
[6]
Escoffre M(2008)Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis Am J Hematol 83 614-617
[7]
Richardson PG(2015)High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma Bone Marrow Transplant 50 1075-1082
[8]
Jacobus SJ(2016)Survival of elderly patients with multiple myeloma – effect of upfront autologous stem cell transplantation Eur J Cancer 62 1-8
[9]
Weller EA(2016)Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study Haematologica 101 1390-1397
[10]
Hassoun H(2021)Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (Maia): overall survival results from a randomized, open-label, phase 3 trial Lancet Oncol 22 1582-1596